Financial Gravity Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Financial Gravity Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11	Closed	-$333	–	1532
2024 Q1	$333	Buy	11 +7	+175%	+$238	﹤0.01%	1499
2023 Q4	$107	Buy	4 +2	+100%	+$60	﹤0.01%	1255
2023 Q3	$41	Sell	2 -15	-88%	-$426	﹤0.01%	1060
2023 Q2	$128	Buy	+17	New	+$256	﹤0.01%	1265
2023 Q1	–	Sell	-8	Closed	-$278	–	1173
2022 Q4	$278	Buy	+8	New	+$77	﹤0.01%	888

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Gravity Asset Management's BBIO Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 11 shares — an estimated $333 sold.

Financial Gravity Asset Management first reported a position in BBIO in Q4 2022 and held it in 5 quarters. The position peaked at $333 in Q1 2024. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

Financial Gravity Asset Management reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 11 BridgeBio Pharma shares in Q2 2024, an estimated $333.
Financial Gravity Asset Management first reported a position in BridgeBio Pharma in Q4 2022 and held it in 5 quarters.
Financial Gravity Asset Management's BridgeBio Pharma position peaked at $333 in Q1 2024.
251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.